Clinical Trial

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)

Investigator

Lee D. Cranmer, MD, PhD, FACP

Complete title:

ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB, AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB, IN PATIENTS WITH ADVANCED OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA OR MYXOFIBROSARCOMA WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY.

Trial phase:

Phase II

Study ID:

NCT04480502

Local study ID:

RG1121198

Summary:

This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A) or envafolimab combined with ipilimumab (cohort B) in patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy.

Trial keywords:

Sarcoma

View Trial at NIH

Enrollment status:

Recruiting

Trial eligibility

** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.

Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Patient Guide to Clinical Trials

For more information about Fred Hutch and to schedule an appointment.

Request an Appointment

Back To: Clinical Trials Homepage